The effects of gasotransmitters on bronchopulmonary dysplasia.
Bronchopulmonary dysplasia (BPD), which remains a major clinical problem for preterm infants, is caused mainly by hyperoxia, mechanical ventilation and inflammation. Many approaches have been developed with the aim of decreasing the incidence of or alleviating BPD, but effective methods are still lacking. Gasotransmitters, a type of small gas molecule that can be generated endogenously, exert a protective effect against BPD-associated lung injury; nitric oxide (NO), carbon monoxide (CO) and hydrogen sulfide (H2S) are three such gasotransmitters. The protective effects of NO have been extensively studied in animal models of BPD, but the results of these studies are inconsistent with those of clinical trials. NO inhalation seems to have no effect on BPD, although side effects have been reported. NO inhalation is not recommended for BPD treatment in preterm infants, except those with severe pulmonary hypertension. Both CO and H2S decreased lung injury in BPD rodent models in preclinical studies. Another small gas molecule, hydrogen, exerts a protective effect against BPD. The nuclear factor erythroid-derived 2 (Nrf2)/heme oxygenase-1 (HO-1) axis seems to play a central role in the protective effect of these gasotransmitters on BPD. Gasotransmitters play important roles in mammals, but further clinical trials are needed to explore their effects on BPD.
['Lin|Hai|H|', 'Wang|Xinbao|X|']
D000280:Administration, Inhalation D000818:Animals D001997:Bronchopulmonary Dysplasia D002248:Carbon Monoxide D064426:Gasotransmitters D006801:Humans D006859:Hydrogen D006862:Hydrogen Sulfide D007231:Infant, Newborn D007234:Infant, Premature D008168:Lung D051379:Mice D009569:Nitric Oxide D051381:Rats
Bronchopulmonary dysplasia Nitric oxide Carbon monoxide Hydrogen Hydrogen sulfide